𝗦𝗲𝗻𝗶𝗼𝗿 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 Dr Owain Millington, CEO Owain has over 20 years’ experience in the immunology space, working in early-stage companies including TC BioPharm, Medisix and Matterhorn Biosciences. He has strong experience in building and leading Discovery and Development teams, successfully identifying new candidates and delivering immunotherapy products into the clinic.
About us
ILC Therapeutics is a specialist UK-based developer of hybrid interferons, a new engineered drug class with improved therapeutic profiles, enabling broad applications across multiple indications. Hybrid interferons combine favourable attributes of specific natural interferon sub-types to produce novel drug candidates designed to deliver reduced toxicity and improved efficacy. ILC Therapeutic’s platform approach has produced two first-in-class lead candidates, Alfacyte™ and Dermacyte™ focused on antiviral and dermatological indications respectively, which are progressing towards the clinic.
- Website
-
http://www.ilctherapeutics.com
External link for ILC Therapeutics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Glasgow
- Type
- Privately Held
Locations
-
Primary
Get directions
Spaces
100 West George Street
Glasgow, G2 1PP, GB
Employees at ILC Therapeutics
Updates
-
Today we announced the completion of a £2.5m fundraise led by Eos, Scottish Enterprise, Medical Incubator Japan K.K. and Robert Kopple, that will support the continued pre-clinical development of our two lead assets, Alfacyte™ and Dermacyte™ as they move towards the clinic. Along with the funding we were delighted to announce the appointments of Owain Millington as Chief Executive Officer, Julie Bailey as Chief Financial Officer, and Dawn Firmin as Chief Operations Officer. https://lnkd.in/eaS_-_z2 #innovation #hybridinterferons
-